OPERATING ROOM


best news: Since most systems offer a trial period, there’s no upfront costs or com- mitments to make which means you can take advantage of the opportunity to show and tell how room disinfection systems can drive down HAI rates and increase patient safety and satisfaction.


As for the many disinfectant products currently available, Healthcare Purchasing News reached out to a variety of different suppliers and asked them to give us their best pitch on what makes their products worth talking about. As expected, all were very passionate and dedicated to provid- ing the best solution and each one also supported claims with research and case- study examples. Here’s some of what they said about the different types of modalities provided.


A mist sets the scene


“HaloMist, when dispensed by a HaloFog- ger, is EPA-validated to produce a 6-log kill (de-activation) of .difii spores in all the nooks and crannies of complex rooms. There can be no approved kill rate higher than 99.9999 percent, so the HDS (Halo Disinfection System) is one of a very small number of systems (one of four) to have that distinction in the U.S.,” asserted said David St.Clair, Chairman, CFO, Halosil International, Inc. “All four such systems are hydrogen peroxide-based, with two using an aerosol and two using hydrogen peroxide vapor. The EPA requires a 99.9999 percent kill rate against C. diff spores to allow any claim against them to be made, the name


HaloMist from Halosil


for which is “sporicidal.” ormally, to be classified as a disinfectant, a kill of at least 99.99 percent against vegetative bacteria and viruses is required. To be an EPA-registered “sanitizer,” a kill rate of 99.9 percent


is generally the target. When our product is initially used as recommended — on operating rooms at night and on isolation rooms upon discharge — the addition to a hospital’s average room turn-around time is mea- sured in minutes,” St. Clair continued. “Pennsylvania Hospital, for instance, fogs only about 4 percent of their patient discharges, and those each take about two hours or less after the normal 30-minute


cleaning. But since it’s only 4 percent, that represents 4 percent of 150 minutes, or 6 minutes of the average. If the hospital takes 45 minutes for the other rooms it disinfects by hand, that represents 96 percent of 45 minutes, or 43.2 minutes. The average, then, is 43.2 + 6, or 49.2 minutes per room vs. 45 min- utes on average for essentially still-infected rooms. And if UV systems take 45-60 minutes or more after normal cleaning to kill any level of C. diff spores, then their number is (4 percent x (30 + ~50)) + (96 percent x 45) = 46.4 minutes for rooms still with at least 70,000 times more C. diff spores left “alive” for the next patient (that’s the difference between 99.9999 percent and 93 percent kill rates). “The HDS is a fraction of the capital cost — roughly 1/6th — of the other three EPA-approved systems, and between 1/4th to 1/12th the cost of any UV system known to us,” St. Clair said. “The bottom line for the Halo Disinfection System is that it is the most effective and most affordable whole-room disinfection system legally on the U.S. market (there may be illegal — i.e. not EPA-approved — chemical disinfection systems out there that also work, in spite of the significant liability riss they bring with them).” Next up is Ed Striefsky, Vice President of Sales and Operations at Bioquell: “We have over  years experience and  scientific publications supporting the use of our tech- nology in a wide range of settings and with proven outcomes reducing HAIs,” he said. “At Bioquell we use high quality 35 percent hydrogen peroxide to deliver a genuinely effective 6-log reduction to all parts of the target area, every time. Each Bioquell cycle can be independently validated by using Geobacillus stearothermophilus biological indicators, so not only is the equipment safe, small, fast, easy to use and regula- tory compliant, but you can also be sure that it works. The important part of what you asked is in the wording ‘whole room disinfection.’ That is what Bioquell Hydro- gen Peroxide Vapor technology offers. We are global leaders in providing this type of disinfection for the entire room, not just high touch areas, with the same level of efficacy throughout. “A Bioquell decontamination cycle,


much like any enhanced decontamination technology, will have a variable duration based on several key environmental fac- tors, most notably the size of the room,”


Striefsky continued. “An average single patient room can be decontaminated in approximately 1.5 to 2 hours depending on conditions, while larger areas may take longer. It is im- portant to note that this represents the complete cycle time, which can be


The


Bioquell System


broadly broken down into 3 stages — vaporization, dwell and aeration. At the end of a Bioquell cycle the room can be immediately reoccupied. We utilize powerful catalytic aera- tion units to rapidly break-


down and remove the vapor following its injection into the room, thus ensuring the fastest possible total cycle time. “Using a Bioquell system will ensure you only have to run a single cycle each time, with no need to move the system around the room, worry about ‘line of sight’ limitations or be concerned about the distance between the generator and the surface to be decontaminated. Bioquell’s products have been consistently proven to be effective against a wide range of target organisms, including bacteria, viruses and even resistant spores. Studies consistently show that manual cleaning alone will leave a high percentage of surfaces within a room contaminated, often over 50 percent. When combined with several extensive studies that show leading U.S. hospitals were able to reduce nosocomial infection by 39 percent to 60 percent while using Bioquell equipment, it starts to paint a picture of the potentially huge cost savings that can be achieved through successfully implementing Bioquell equipment or our in-house daily decontamination service called the Bioquell Proactive.” Nevoa, Inc., hangs its hat on offering a patented, hospital-grade surface disin- fecting system approved for atomizing an EPA-registered solution that contains the active ingredient Hypochlorous Acid (HOCl). “The system is comprised of two components. Nimbus — a machine that deploys (“atomizes”) a liquid solution into a hospital room to disinfect all surfaces and equipment, with no line-of-sight is- sues, and Microburst — an EPA-registered solution whose active ingredient is Hypo- chlorous Acid (HOCl),” asserted Ernest Cunningham, President, Nevoa, Inc. “To- gether, the Nimbus + Microburst system eradicates pathogens in patient rooms, lowering a patient’s risk of acquiring Healthcare Associated Infections (HAI),


Page 16 hpnonline.com • HEALTHCARE PURCHASING NEWS • September 2019 15


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56